These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 34667128)

  • 1. New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD.
    Takeshita Y; Fujikawa S; Serizawa K; Fujisawa M; Matsuo K; Nemoto J; Shimizu F; Sano Y; Tomizawa-Shinohara H; Miyake S; Ransohoff RM; Kanda T
    Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34667128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Purified IgG from aquaporin-4 neuromyelitis optica spectrum disorder patients alters blood-brain barrier permeability.
    Cobo-Calvo A; Ruiz A; Richard C; Blondel S; Cavagna S; Strazielle N; Ghersi-Egea JF; Giraudon P; Marignier R
    PLoS One; 2020; 15(9):e0238301. PubMed ID: 32881954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low Frequency Ultrasound With Injection of NMO-IgG and Complement Produces Lesions Different From Experimental Autoimmune Encephalomyelitis Mice.
    Xiang W; Xie C; Luo J; Zhang W; Zhao X; Yang H; Cai Y; Ding J; Wang Y; Hao Y; Zhang Y; Guan Y
    Front Immunol; 2021; 12():727750. PubMed ID: 34721390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models.
    Wu Y; Zhong L; Geng J
    Mult Scler Relat Disord; 2019 Jan; 27():412-418. PubMed ID: 30530071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autocrine MMP-2/9 secretion increases the BBB permeability in neuromyelitis optica.
    Tasaki A; Shimizu F; Sano Y; Fujisawa M; Takahashi T; Haruki H; Abe M; Koga M; Kanda T
    J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):419-30. PubMed ID: 24259591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FTY720 Exacerbates Blood-Brain Barrier Dysfunction Induced by IgG Derived from Patients with NMO and MOG Disease.
    Yoshimura S; Nakagawa S; Takahashi T; Tanaka K; Tsujino A
    Neurotox Res; 2021 Aug; 39(4):1300-1309. PubMed ID: 33999356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
    Fung S; Shirley M
    CNS Drugs; 2023 Apr; 37(4):363-370. PubMed ID: 36933107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment.
    Vincent T; Saikali P; Cayrol R; Roth AD; Bar-Or A; Prat A; Antel JP
    J Immunol; 2008 Oct; 181(8):5730-7. PubMed ID: 18832732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of NMO-IgG on the interleukin-6 cascade in astrocytes via activation of the JAK/STAT3 signaling pathway.
    Du L; Chang H; Xu W; Wei Y; Wang Y; Yin L; Zhang X
    Life Sci; 2020 Oct; 258():118217. PubMed ID: 32768575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Astrocytic Interleukin-15 Reduces Pathology of Neuromyelitis Optica in Mice.
    Li Z; Han J; Ren H; Ma CG; Shi FD; Liu Q; Li M
    Front Immunol; 2018; 9():523. PubMed ID: 29616032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
    Carnero Contentti E; Correale J
    J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental mouse model of NMOSD produced by facilitated brain delivery of NMO-IgG by microbubble-enhanced low-frequency ultrasound in experimental allergic encephalomyelitis mice.
    Luo J; Xie C; Zhang W; Cai Y; Ding J; Wang Y; Hao Y; Zhang Y; Guan Y
    Mult Scler Relat Disord; 2020 Nov; 46():102473. PubMed ID: 32919181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms.
    Zhang H; Bennett JL; Verkman AS
    Ann Neurol; 2011 Dec; 70(6):943-54. PubMed ID: 22069219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GRP 78 antibodies are associated with clinical phenotype in neuromyelitis optica.
    Shimizu F; Takeshita Y; Hamamoto Y; Nishihara H; Sano Y; Honda M; Sato R; Maeda T; Takahashi T; Fujikawa S; Kanda T
    Ann Clin Transl Neurol; 2019 Oct; 6(10):2079-2087. PubMed ID: 31568704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro.
    Takeshita Y; Obermeier B; Cotleur AC; Spampinato SF; Shimizu F; Yamamoto E; Sano Y; Kryzer TJ; Lennon VA; Kanda T; Ransohoff RM
    Neurol Neuroimmunol Neuroinflamm; 2017 Jan; 4(1):e311. PubMed ID: 28018943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuromyelitis optica pathogenesis and aquaporin 4.
    Graber DJ; Levy M; Kerr D; Wade WF
    J Neuroinflammation; 2008 May; 5():22. PubMed ID: 18510734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica.
    Shimizu F; Schaller KL; Owens GP; Cotleur AC; Kellner D; Takeshita Y; Obermeier B; Kryzer TJ; Sano Y; Kanda T; Lennon VA; Ransohoff RM; Bennett JL
    Sci Transl Med; 2017 Jul; 9(397):. PubMed ID: 28679661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinally extensive NMO spinal cord pathology produced by passive transfer of NMO-IgG in mice lacking complement inhibitor CD59.
    Zhang H; Verkman AS
    J Autoimmun; 2014 Sep; 53():67-77. PubMed ID: 24698947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Passively transferred human NMO-IgG exacerbates demyelination in mouse experimental autoimmune encephalomyelitis.
    Saini H; Rifkin R; Gorelik M; Huang H; Ferguson Z; Jones MV; Levy M
    BMC Neurol; 2013 Aug; 13():104. PubMed ID: 23927715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental Neuromyelitis Optica Induces a Type I Interferon Signature in the Spinal Cord.
    Oji S; Nicolussi EM; Kaufmann N; Zeka B; Schanda K; Fujihara K; Illes Z; Dahle C; Reindl M; Lassmann H; Bradl M
    PLoS One; 2016; 11(3):e0151244. PubMed ID: 26990978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.